Bcr-Abl
Os inibidores de Bcr-Abl são terapias direcionadas que inibem a proteína de fusão Bcr-Abl, que é formada devido à translocação do cromossomo Filadélfia e é um dos principais fatores da leucemia mieloide crônica (LMC). Essa proteína também influencia a angiogênese, contribuindo para a progressão do tumor. Os inibidores de Bcr-Abl são essenciais no tratamento da LMC e estão sendo explorados por seu potencial em inibir a angiogênese em vários tipos de câncer. Na CymitQuimica, oferecemos inibidores de Bcr-Abl de alta qualidade para apoiar sua pesquisa em biologia do câncer, angiogênese e terapias direcionadas.
Produtos da "Bcr-Abl"
Ordenar por
GNF-5
CAS:GNF-5, non-ATP Bcr-Abl inhibitor (IC50: 0.22±0.1 uM, wild-type), improves upon GNF-2 with better pharmacokinetics.Fórmula:C20H17F3N4O3Pureza:98% - 99.98%Cor e Forma:SolidPeso molecular:418.37Pivanex
CAS:Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.Fórmula:C10H18O4Pureza:≥98%Cor e Forma:SolidPeso molecular:202.25AST 487
CAS:AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.Fórmula:C26H30F3N7O2Pureza:98.17% - 99.56%Cor e Forma:SolidPeso molecular:529.56Ref: TM-T4053
1mg37,00€2mg52,00€5mg79,00€10mg119,00€25mg187,00€50mg354,00€100mg528,00€500mg1.159,00€1mL*10mM (DMSO)92,00€Multi-kinase inhibitor 1
CAS:Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.Fórmula:C20H17F3N4O3Pureza:99.34%Cor e Forma:SolidPeso molecular:418.37Nilotinib
CAS:Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor. Nilotinib has antitumor activity and may be used in CML. Cost-effective and quality-assured.Fórmula:C28H22F3N7OPureza:99.61% - 99.83%Cor e Forma:Off-White SolidPeso molecular:529.52HG-7-85-01
CAS:HG-7-85-01 is a novel ATP-competitive and type II tyrosine kinase inhibitor targeting both wild-type and watchman mutant BCR-ABL, PDGFRα, Kit, and Src kinases.Fórmula:C31H31F3N6O2SPureza:98.08%Cor e Forma:SolidPeso molecular:608.68Imatinib impurities3
CAS:Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.Fórmula:C24H20ClN5OPureza:97.05%Cor e Forma:SolidPeso molecular:429.9Olverembatinib dimesylate
CAS:Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).Fórmula:C29H27F3N6O·2CH4O3SPureza:100% - 99.81%Cor e Forma:SolidPeso molecular:724.77Ref: TM-T2429
1mg39,00€2mg51,00€5mg84,00€10mg119,00€25mg229,00€50mg319,00€100mg474,00€1mL*10mM (DMSO)120,00€BCR-ABL-IN-7
CAS:BCR-ABL-IN-7 is an inhibitor of ABL kinase activity in WT and T315I mutants.BCR-ABL-IN-7 can be used in chronic myeloid leukemia (CML) research.Fórmula:C19H16FN3O3SPureza:98.28%Cor e Forma:SolidPeso molecular:385.41Bosutinib
CAS:Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.Fórmula:C26H29Cl2N5O3Pureza:98.98% - 99.9%Cor e Forma:Yellowish-Orange Or Pink To Brownish Solid Solid PowderPeso molecular:530.45Nocodazole
CAS:Nocodazole: synthetic microtubule polymerization blocker, also impedes Abl with low IC50; binds to beta-tubulin.Fórmula:C14H11N3O3SPureza:98% - 99.91%Cor e Forma:Physical Description White Powder (Ntp 1992)Peso molecular:301.32Ref: TM-T2802
5mg37,00€10mg55,00€25mg99,00€50mg168,00€100mg283,00€200mg420,00€500mg682,00€1mL*10mM (DMSO)40,00€BCR-ABL-IN-10
BCR-ABL-IN-10 (compound B4) is a covalent BCR-ABL inhibitor featuring an arylvinylsulfonate (AVS) moiety, demonstrating an IC50 of 43.1 nM against ABL kinase. It forms a covalent and stable adduct with ABL kinase, enabling the sustained inhibition of intrinsic BCR-ABL activity. This compound is utilized in the study of chronic myeloid leukemia (CML).Fórmula:C24H22N4O5SCor e Forma:SolidPeso molecular:478.52GNF-2
CAS:GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.Fórmula:C18H13F3N4O2Pureza:98.17% - ≥95%Cor e Forma:SolidPeso molecular:374.32PD180970
CAS:PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit.Fórmula:C21H15Cl2FN4OPureza:98.47%Cor e Forma:SolidPeso molecular:429.27PF-06651481-00
CAS:PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.Fórmula:C26H29Cl2N5O3Pureza:97.57%Cor e Forma:SolidPeso molecular:530.45N-Desmethyl imatinib
CAS:N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.Fórmula:C28H29N7OPureza:98.60%Cor e Forma:Off-White To Pale-Yellow SolidPeso molecular:479.58Ref: TM-T11641
1mg92,00€5mg170,00€10mg319,00€25mg540,00€50mg777,00€100mg1.074,00€1mL*10mM (DMSO)178,00€AKE-72
CAS:AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.Fórmula:C30H29F3N6OPureza:98.3%Cor e Forma:SoildPeso molecular:546.59Radotinib
CAS:Radotinib (IY-5511), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notablyFórmula:C27H21F3N8OPureza:99.13% - 99.97%Cor e Forma:SolidPeso molecular:530.5LXH254
CAS:LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.Fórmula:C25H25F3N4O4Pureza:98.3% - 99.92%Cor e Forma:SolidPeso molecular:502.49Ref: TM-T11898
1mg52,00€5mg122,00€10mg185,00€25mg363,00€50mg567,00€100mg690,00€200mg948,00€500mg1.444,00€1mL*10mM (DMSO)135,00€AT9283
CAS:AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).Fórmula:C19H23N7O2Pureza:99.83% - 99.98%Cor e Forma:SolidPeso molecular:381.43Ref: TM-T3068
1mg47,00€2mg60,00€5mg95,00€10mg170,00€25mg299,00€50mg499,00€100mg723,00€1mL*10mM (DMSO)97,00€
